Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$887.16 USD

887.16
1,970,679

+1.61 (0.18%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Jul 17, 2023

by Zacks Equity Research

Companies in The News Are: C, ERIC, STT, LLY.

Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio

by Zacks Equity Research

For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog Highlights Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices

by Zacks Equity Research

Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices are part of the Zacks top Analyst Blog .

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $440.60, moving +0.28% from the previous trading session.

Sheraz Mian headshot

Top Analyst Reports for Visa, UnitedHealth & Eli Lilly

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).

Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs

by Zacks Equity Research

Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.

Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Eli Lilly (LLY) Stock Moves -0.53%: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $463.21, marking a -0.53% move from the previous day.

Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY

by Zacks Equity Research

Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.

Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?

by Zacks Equity Research

Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.

Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly

by Zacks Equity Research

Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $464.49 in the latest trading session, marking a +1.26% move from the prior day.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSPH

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Stock Down on Halting Development of Obesity Drug

by Zacks Equity Research

Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $458.84, moving +0.25% from the previous trading session.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

by Zacks Equity Research

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

by Zacks Equity Research

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

by Zacks Equity Research

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.